On August 19, in collaboration with 3 head and neck cancer nonprofits, the NFOSD hosted a meeting that gave patients and families impacted by chronic dry mouth a way to share the impact of living with xerostomia. The meeting gave FDA and other key stakeholders, including medical product developers, health care providers, and federal partners, an important opportunity to hear directly from patients, their families, caregivers, and patient advocates about the symptoms that matter most to them, the impact it has on patients’ daily lives, and patients’ experiences with currently available treatments. This input informs FDA’s decisions and oversight during drug development in addition to their review of a drug’s marketing application.